Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Fabrazyme Coverage | OpenPayer
    Ask Trek AI about this page
    Draftblue cross blue shield - tennesseePolicy ID_CHS_20542026_0926

    Agalsidase Beta (Fabrazyme®) Coverage for Fabry Disease

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_20542026_0926 alerts

    Get alerted when Policy ID_CHS_20542026_0926 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of intravenous Fabrazyme for adult and pediatric members aged 2 years and older with confirmed Fabry disease. Coverage requires clinical, diagnostic, prescriber-specialty, and non-combination-use criteria; other indications are not medically necessary.

    Policy Summary
    Payerblue cross blue shield - tennessee
    PolicyAgalsidase Beta (Fabrazyme®) Coverage for Fabry Disease
    Policy CodePolicy ID_CHS_20542026_0926
    Change TypeNo material change
    Effective DateDec 1, 202612d
    Next Review DateN/A
    Key ActionSubmit diagnostic testing and baseline clinical documentation with initial requests, and document positive response to therapy for continuation requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Fabry diseaseCovered indication
    Age 2+Minimum treatment age
    12 monthsInitial authorization
    12 monthsContinuation authorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 mg/kg every 2 weeksDosing regimen

    Coverage Criteria

    Initial Therapy Criteria

    Covered for Fabry disease when all of the following criteria are met:

    Initial therapy

    • Age: Member is 2 years of age or older.>= 2 years
    • Diagnostic confirmation

      • Enzyme assay demonstrates a deficiency of alpha-galactosidase enzyme activity.
      • Genetic testing confirms the diagnosis.
      • Obligate carrier: Member is a symptomatic obligate carrier.
    • Clinical manifestations: Member exhibits clinical signs and symptoms of Fabry disease at baseline.

      Examples include acroparesthesias, angiokeratomas, gastrointestinal symptoms, and corneal opacities.

    • Non-combination use: Fabrazyme will not be used in combination with Elfabrio or Galafold.

    Continuation Therapy Criteria

    Continuation coverage may be granted when the member is responding to therapy:

    Continuation therapy

    • Covered indication: The reauthorization request is for an indication listed in the coverage criteria.
    • Positive response: Member demonstrates response to therapy, including reduction in disease biomarkers or inclusions, improvement or stabilization of renal function, or pain reduction.

      Response may be documented in chart notes or medical records.

    Combination-use restriction: Fabrazyme must not be used in combination with Elfabrio or Galafold.

    Noncovered indications: Uses other than the FDA-approved treatment of confirmed Fabry disease in adult and pediatric patients 2 years of age and older are considered experimental/investigational and not medically necessary.

    Initial Fabry Disease Authorization

    Fabry Disease Initial Authorization

    Authorization of 12 months may be granted for Fabrazyme treatment of Fabry disease when all of the following criteria are met:

    Fabry disease initial authorization

    • Age: Member is 2 years of age or older.>= 2 years
    • Diagnostic confirmation

      • Enzyme assay demonstrates a deficiency of alpha-galactosidase enzyme activity.
      • Genetic testing confirms the diagnosis.

    Continuation Authorization

    Fabry Disease Reauthorization

    Authorization of 12 months may be granted for continued treatment when both of the following criteria are met:

    Fabry disease reauthorization

    • Covered indication: The reauthorization request is for an indication listed in the coverage criteria.
    • Response to therapy: Member demonstrates a positive response to therapy, such as reduction in plasma GL-3/Gb3, reduction in GL-3/Gb3 inclusions or plasma lyso-GL-3, improvement and/or stabilization in renal function, or pain reduction.

    Provider Requirements and Request Guidance

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for Fabrazyme. Initial authorization may be granted for 12 months when all coverage criteria are met, including confirmed Fabry disease, qualifying baseline clinical signs and symptoms, and no concurrent use with Elfabrio or Galafold.

    Prior Authorization

    Continuation Prior Authorization

    Reauthorization may be granted for 12 months when the member continues to meet the applicable coverage requirements and is responding to therapy.

    • Document a positive response, such as reduced plasma globotriaosylceramide (GL-3/Gb3) or plasma lyso-GL-3, improved or stabilized renal function, or reduced pain.
    Note

    Qualified Prescriber

    Policy Background

    Fabry disease is the covered indication for Fabrazyme in adult and pediatric patients aged 2 years and older with confirmed disease. Clinical findings that may support treatment include acroparesthesias, angiokeratomas, gastrointestinal symptoms, and corneal opacities documented at baseline.

    Dosing and Quantity Limits

    Quantity Limits
    MedicationFabrazyme (agalsidase beta)
    Covered diagnosisFabry disease
    Route of administrationIntravenous
    Minimum age2 years and older
    Maximum dosing regimen1 mg/kg every 2 weeks
    Policy Summary
    Payerblue cross blue shield - tennessee
    PolicyAgalsidase Beta (Fabrazyme®) Coverage for Fabry Disease
    Policy CodePolicy ID_CHS_20542026_0926
    Change TypeNo material change
    Effective DateDec 1, 202612d
    Next Review DateN/A
    Key ActionSubmit diagnostic testing and baseline clinical documentation with initial requests, and document positive response to therapy for continuation requests.
    SourceLink
    On This Page
    Coverage CriteriaInitial Fabry Disease AuthorizationContinuation AuthorizationProvider Requirements and Request GuidancePolicy BackgroundDosing and Quantity Limits
    Obligate carrier: Member is a symptomatic obligate carrier.
  1. Clinical manifestations: Member exhibits clinical signs and symptoms of Fabry disease at baseline.

    Examples include acroparesthesias, angiokeratomas, gastrointestinal symptoms, and corneal opacities.

  2. Qualified prescriber: The medication is prescribed by a physician specializing in metabolic disease and/or lysosomal storage disorders, or is prescribed in consultation with such a physician.
  3. Non-combination use: Fabrazyme will not be used in combination with Elfabrio or Galafold.
  4. Fabrazyme must be prescribed by, or prescribed in consultation with, a physician who specializes in treating metabolic disease and/or lysosomal storage disorders.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Noncovered Indications

    Fabrazyme is covered for confirmed Fabry disease in adults and pediatric patients age 2 years and older when approval criteria are met. All other indications are considered experimental/investigational and not medically necessary.

    Denial Risk

    Coverage Criteria Not Met

    Coverage may be denied when Fabry disease is not confirmed or when required clinical criteria are absent. The member must meet the applicable requirements, including age 2 years or older, qualifying diagnostic evidence or symptomatic obligate-carrier status, baseline clinical signs and symptoms, and no combination use with Elfabrio or Galafold.

    Note

    Specialist Involvement Required

    When the prescribing physician is not a metabolic disease or lysosomal storage disorder specialist, document that treatment was prescribed in consultation with a physician who specializes in one of these areas.